UNITED THERAPEUTICS CORP

United Therapeutics’ insider trades reveal executive confidence, while new ATS‑conference data could reshape respiratory therapy practice and policy.

United Therapeutics’ recent insider trades reveal a transparent, strategy‑driven approach—balancing capital allocation, value‑based reimbursement, and supply‑chain resilience to strengthen its pulmonary hypertension pipeline and investor prospects.

Insider trades by UTH CEO Martina Rothblatt show no strategic shift, but the company faces patent cliffs for Macitentan. Learn how UTH plans pricing, pipeline, and M&A to protect growth and compete in pulmonary hypertension.

Explore how United Therapeutics’ CEO trading plan reveals key insights into capital discipline, executive incentives, and regulatory compliance in the specialty‑pharma sector.

United Therapeutics’ Tyvaso breakthrough in the TETON‑1 study sparks investor buzz, boosting pricing targets and buy ratings as the company scales IPF access while navigating reimbursement hurdles.

United Therapeutics’ analyst upgrades to mid‑$600s reflect strong QALY‑based pricing, digital‑manufacturing gains and patient‑access wins that drive 8‑10 % growth.

United Therapeutics reveals its strategy to dominate pulmonary hypertension: market access, competitive edge, patent plans, and M&A prospects—all at TD Cowen.

United Therapeutics updates at JHC: focus on prostacyclin PAH therapies, value‑based contracts, patent strategy, and potential M&A for growth.

United Therapeutics Corporation reported record third-quarter 2025 results, exceeding Wall Street expectations with earnings per share of $7.16 and revenue of $799 million, driven by growth in its core product portfolio and strong operating cash flo…

United Therapeutics’ stock has seen a notable 11.9% gain since its last earnings report, driven by the company’s growing financial performance and investor confidence.